Highlights•Type I IFN is implicated in SLE pathogenesis by multiple lines of evidence,
including genetics and induction of SLE by IFN treatment.•Nucleic-acid sensing pathways …

The type I interferon pathway has been implicated in the pathogenesis of a number of
rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis …

Systemic lupus erythematosus is a chronic autoimmune disease characterized by loss of
tolerance against nuclear and cytoplasmic self-antigens, induction of immunity and tissue …

Systemic lupus erythematosus (SLE) is a chronic inflammatory and autoimmune disease
characterised by multiple organ involvement and a large number of complications. SLE …

The serum level of IL-33 was upregulated in systemic lupus erythematosus (SLE), which
may be used as biomarkers and/or therapeutic targets for SLE. The aim of this study was to …

Data reproducibility and single-center bias are concerns in preclinical research and
compromise translation from animal to human. Multicenter preclinical randomized controlled …

B cells in general and BAFF (B cell activating factor of the tumor necrosis factor [TNF] family)
in particular have been primary targets of recent clinical trials in systemic lupus …

The immune system, functioning as the body's “defense army”, plays a role in surveillance,
defense. Any disruptions in immune system can lead to the development of immune-related …

Introduction: Treatment of systemic lupus erythematosus (SLE) represents a challenge due
to variable disease manifestations, clinical course, and outcome. Long-term outcome in SLE …

Objective To characterise patients with active SLE based on pretreatment gene expression-
defined peripheral immune cell patterns and identify clusters enriched for potential …